Ariane Medical Systems

What Ariane Medical Systems does

Ariane Medical Systems Ltd is a UK-based private medical device company founded in 2005 and headquartered in Alfreton, Derbyshire, that designs, manufactures, and supplies the Papillon+™ X-ray brachytherapy system. The system's core is the patented Micronode™ X-ray generator, a wireless and portable unit capable of delivering up to 20 Gy/min with a 310° homogeneous beam, supporting treatments in brachytherapy suites, treatment rooms, and operating theatres with minimal shielding. The Papillon+ platform is used for three principal clinical applications: contact X-ray brachytherapy (CXB) for rectal cancer, intraoperative radiotherapy (IORT) for breast cancer, and superficial skin cancer treatment, and is supported by ancillary products including the Papillon+ Workstation, the Prefectus quality assurance device, and the Monitus door warning system.

The company sells capital equipment to NHS trusts, private hospitals, and international cancer centres via a direct enterprise field-sales model complemented by regional distribution partnerships, including Leo Medical in India and a co-marketing arrangement with Clerad in France. Treatment economics at the hospital level are approximately £6,000 per NHS procedure and £9,000 per private procedure, and the company has supported treatment of over 5,000 patients cumulatively since 2009, with four established UK sites (Clatterbridge, Nottingham City, Royal Surrey, Queens Centre Hull) and additional international installations. The business has received a 2025 updated NICE recommendation for low-energy CXB in operable rectal cancer patients, and expects 8-10 additional system installations by end-2026. Ariane is led by CEO Simon Bernard and VP International Sales Mark Davies-Cousins; ownership is private with no disclosed institutional investors, parent company, or external funding rounds, and revenue figures are not publicly disclosed.

Name

Ariane Medical Systems

Legal name

Ariane Medical Systems Ltd

Website

https://arianemedicalsystems.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Ariane Medical Systems is a UK-based medical device company that designs, manufactures, and sells the Papillon+ X-ray brachytherapy system for organ-preserving treatment of rectal, breast, and skin cancers, serving NHS trusts, private hospitals, and international cancer centres via direct sales and distribution partners.

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYEUAKAIAD

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

SECONDARYHLAHABAA

X-ray & Fluoroscopy Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

SECONDARYHLAHABAG

Interventional Radiology & Image-Guided Therapy Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

• Radiation oncology equipment
• X-ray brachytherapy systems
• Intraoperative radiotherapy devices
• Contact brachytherapy systems
• Cancer treatment hardware

Headquarters

HQ city

Alfreton

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of Papillon+ X-ray brachytherapy systems and related equipment (X-ray generators, workstations, quality assurance devices) to hospitals and cancer treatment centres. Capital equipment sales model with installation, training and support services.
2. Treatment Procedures: Revenue from Papillon treatments delivered at NHS and private healthcare facilities. NHS cost approximately £6,000 per treatment; private treatment approximately £9,000.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Ariane Medical Systems designs, develops, and manufactures low-energy X-ray brachytherapy systems, principally the Papillon+ platform, used by hospitals and cancer treatment centres for contact radiotherapy of rectal cancer, intraoperative radiotherapy (IORT) for breast cancer, and treatment of superficial skin cancers. The system is built on the company's patented Micronode X-ray generator, which delivers up to 20 Gy/min via a cable-free, wireless, mobile unit with minimal shielding requirements.

Product overview

Ariane Medical Systems offers the Papillon+™ X-ray Brachytherapy System as its core product, supported by the patented Micronode™ X-ray Generator technology capable of delivering up to 20 Gy/min. The product portfolio includes the Papillon+ Workstation for system operation, the Monitus Door Warning System for safety, and the Prefectus Quality Assurance Device. The flagship Papillon+ system enables three primary treatment applications: Papillon Contact X-ray Brachytherapy for rectal cancer, Intraoperative Radiotherapy (IORT) for breast cancer, and superficial skin cancer treatment. The portable, cable-free, wireless system can be used in brachytherapy suites, treatment rooms, and operating theatres with minimal shielding requirements.

Differentiator

Problem solved

Functional benefit

Brands

• Papillon+: X-ray brachytherapy system for targeted cancer treatment including rectal, breast, and skin cancer applications
• Papillon Technique
• Micronode
• Papillon+ Workstation
• Prefectus
• Monitus

Products and services

• Papillon+ X-ray Brachytherapy System Mobile, cable-free, wireless X-ray brachytherapy system suspended on an articulated height-adjustable support arm with an integrated electronics cabinet and shielded parking tube. Delivers contact brachytherapy for rectal cancer, intraoperative radiotherapy (IORT) for breast cancer, and superficial skin cancer treatments. Sold to hospitals, NHS trusts, and cancer treatment centres.
• Papillon+ Workstation All-in-one workstation that enables clinical staff to safely operate the Papillon+ system, supporting treatments in dedicated brachytherapy suites or operating rooms.
• Monitus Door Warning System Door warning system providing radiation safety indication and operator protection during Papillon+ treatments.
• Prefectus Quality Assurance Device Quality assurance device for verifying precise and safe operation of the Papillon+ system prior to clinical use.
• Micronode X-ray Generator Patented X-ray generator technology delivering up to 20 Gy/min directly to tumours or IORT surgical cavities with a 310° homogeneous beam and significantly reduced treatment times. Forms the core radiation source of the Papillon+ system.

Quantifiable outcome

• 80-96% organ preservation rate in patients
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and major.

• Leo Medical (India)coreChannel Partner/ Reseller/ Distributor · 3 February 2026Commercial partnership established in India with Venkatesan KS from Leo Medical. Includes clinical presentations at Tata Memorial Hospital and expansion support for Papillon technology across the region.
• Tata Memorial HospitalmajorStrategic or Co-development Partner · 30 January 2026Clinical engagement and presentation on Papillon CXB technology at Tata Memorial Hospital, one of India's leading cancer institutions. Partnership supports clinical education and technology adoption.
• Clatterbridge Cancer CentrecoreStrategic or Co-development Partner · 24 September 2025Long-standing partnership for Papillon CXB training (19 consecutive years). Hosted by Prof Arthur Sun Myint and Prof Jean-Pierre Gerard. Training events bring together clinicians from UK and internationally.
• CleradcoreStrategic or Co-development Partner · 1 July 2025Joint showcase at SFCO 2025 in France presenting integrated breast cancer care solutions combining Clerad's Gamma Sentinel Node Detector, Mozart Tumour Margin Radiology Device, and Ariane's Papillon+ IORT Solution. Partnership focused on comprehensive early-stage breast cancer care approach.
• St Bartholomew's Hospital NHS TrustcoreImplementation/ SI/ Consulting Partner · 1 June 2025Installation of Papillon CXB system at St Barts Centre of Excellence in London, marking first London centre to offer this technology. Ariane supported clinical team for first patient treatments in January 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Becton, Dickinson and Company (BD): Through its BD Interventional / Bard acquisitions, BD supplies radioactive seed brachytherapy (e.g., prostate) and adjacent interventional oncology devices. While focused on seed-based rather than X-ray-based brachytherapy, BD overlaps materially with Ariane in hospital oncology purchasing decisions and clinical-training ecosystems.
• Varian Medical Systems (Siemens Healthineers): Largest installed base of linear accelerators, brachytherapy afterloaders, and treatment-planning software globally. Varian's HDR brachytherapy and external-beam systems are the principal alternative modalities hospitals weigh against adopting Papillon+ for rectal and breast IORT use cases.
• Elekta: Global leader in radiation therapy and radiosurgery hardware (linacs, Gamma Knife) and the dominant HDR brachytherapy afterloader vendor. Ariane's Papillon competes with Elekta's HDR/IRidium brachytherapy workflow for rectal and gynaecological cancers, making Elekta the most direct adjacent competitor in the oncology treatment room.
• Carl Zeiss Meditec (Intrabeam legacy): Historically commercialised the Intrabeam IORT platform for breast IORT — a direct procedural alternative to Papillon+ in the same surgical workflow. Zeiss Meditec's broader surgical-microscopy footprint and installed base represent the historical default for many UK/European IORT conversations.
• Eckert & Ziegler (Radiopharma/Isotope Products): Supplies radioactive sources, seeds and afterloader components used in brachytherapy — competing for hospital radiation-oncology budgets in adjacent modality. Useful comparable for capital-equipment-and-consumables business models in radiation therapy.

Direct peers

• IsoAid: Brachytherapy seed manufacturer specialising in low-dose-rate and high-dose-rate radioactive sources. Comparable to Ariane as a small, specialised oncology-device vendor with similar hospital-customer concentration and clinical-evidence-driven adoption cycle.
• Theragenics: Specialty brachytherapy seeds and accessories supplier with focus on prostate and gynecological cancers. Smaller, niche player comparable to Ariane in scale and specialisation, with overlapping clinical end-users (radiation oncologists) and a similar go-to-market model.
• IntraOp Medical: Developer of the Mobetron intraoperative electron-beam radiation therapy system, directly competing with Papillon+ for the breast-IORT indication and similar accessible-tumour workflows in oncology centers.
• Sensus Healthcare: US-listed specialty device company marketing the SRT-100 superficial radiation therapy system for non-melanoma skin cancer. Sensus is the closest direct competitor in Papillon's skin-cancer indication, and also adjacent in IORT-adjacent radiation therapy workflows.

Emerging players

• iCAD: Radiation-therapy-AI and Xoft IORT system vendor offering an alternative electronic brachytherapy approach. Overlaps with Ariane in IORT positioning and in cancer-care software/services, though more software-heavy than Ariane's device-centric model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ArianeMedical
• YouTubeyoutube.com/channel/UCSJYYtznvNs-57mKvsy1Imw
• LinkedInlinkedin.com/company/ariane-medical-systems-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ariane Medical Systems